Our News and Events

Come meet us at an upcoming event.

March 27-28, 2019   MassBIO Annual meeting
Cambridge, MA

March 29 - April 3, 2019   American Association for Cancer Research (AACR) Annual Meeting
Atlanta, Georgia

April 14-17, 2019   World Vaccine Congress Washington
Washington, D.C.

May 9-10, 2019   Convergence Forum
Chatham, MA

May 31 - June 4, 2019   American Society Of Clinical Oncology (ASCO) Annual Meeting
Chicago, IL

June 3-6, 2019   BIO International 2019
Philadelphia, PA

October 8, 2018   ImaginAb Announces Collaboration with Merck for CD8 T cell I/O Imaging Agent
October 1, 2018   Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors
July 24, 2018   Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
July 12, 2018   Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
July 12, 2018   Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
May 3, 2018   Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
March 7, 2018   Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
February 21, 2018   Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
November 16, 2017   Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck
October 10, 2017   KalVista Pharmaceuticals Announces Collaboration with Merck
September 6, 2017   Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology
July 27, 2017   AstraZeneca and Merck Establish Strategic Oncology Collaboration
June 20, 2017   SerImmune Inc. Announces Discovery and Development Collaboration with Merck
May 25, 2017   Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau
March 17, 2017   New partnership to accelerate development of treatments for neurological diseases
March 1, 2017   GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early
January 5, 2017   Cerveau Technologies, Inc. Signs License Agreement with Merck for Novel Investigational Tau Imaging Agent